• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.

    2/14/25 4:06:25 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EPIX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)


    ESSA Pharma Inc.

    (Name of Issuer)


    Common Shares, no par value per share (the "Shares")

    (Title of Class of Securities)


    29668H708

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    29668H708


    1Names of Reporting Persons

    PFM Health Sciences, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    29668H708


    1Names of Reporting Persons

    PFM Health Sciences GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    29668H708


    1Names of Reporting Persons

    Partner Asset Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    29668H708


    1Names of Reporting Persons

    Brian D. Grossman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ESSA Pharma Inc.
    (b)Address of issuer's principal executive offices:

    999 West Broadway Suite 720 British Columbia, CA, V5Z 1K5
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being jointly filed by PFM Health Sciences, LP ("PFM"), PFM Health Sciences GP, LLC ("PFM-GP"), Partner Asset Management, LLC ("PAM"), and Brian D. Grossman ("Grossman" and, collectively with PFM, PFM-GP, and PAM, the "Reporting Persons"). PFM-GP is the general partner of PFM and the manager of PAM. Grossman is the sole member of PFM-GP. The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is c/o PFM Health Sciences, LP, 475 Sansome Street, Suite 1720, San Francisco, California 94111
    (c)Citizenship:

    PFM is organized as a limited partnership under the laws of the State of Delaware. Each of PFM-GP and PAM is organized as a limited liability company under the laws of the State of Delaware. Grossman is a U.S. citizen.
    (d)Title of class of securities:

    Common Shares, no par value per share (the "Shares")
    (e)CUSIP No.:

    29668H708
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1. Each of PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC may be deemed to beneficially own 0 Shares. 2. Mr. Grossman may be deemed to beneficially own 0 Shares.
    (b)Percent of class:

    1. The number of Shares that each of PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC may be deemed to beneficially own constitutes 0% of the Shares outstanding. 2. The number of Shares that Mr. Grossman may be deemed to beneficially own constitutes 0% of the Shares outstanding.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1. Each of PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC: 0 2. Mr. Grossman: 0

     (ii) Shared power to vote or to direct the vote:

    1. Each of PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC: 0 2. Mr. Grossman: 0

     (iii) Sole power to dispose or to direct the disposition of:

    1. Each of PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC: 0 2. Mr. Grossman: 0

     (iv) Shared power to dispose or to direct the disposition of:

    1. Each of PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC: 0 2. Mr. Grossman: 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    PFM Health Sciences, LP
     
    Signature:/s/ Darren Mooney
    Name/Title:Darren Mooney, Authorized Signatory
    Date:02/14/2025
     
    PFM Health Sciences GP, LLC
     
    Signature:/s/ Darren Mooney
    Name/Title:Darren Mooney, Authorized Signatory
    Date:02/14/2025
     
    Partner Asset Management, LLC
     
    Signature:/s/ Darren Mooney
    Name/Title:Darren Mooney, Authorized Signatory
    Date:02/14/2025
     
    Brian D. Grossman
     
    Signature:/s/ Darren Mooney
    Name/Title:Darren Mooney, attorney-in-fact*
    Date:02/14/2025

    Comments accompanying signature:  * Darren Mooney is signing on behalf of Brian Grossman as attorney-in-fact pursuant to a power of attorney dated February 1, 2024, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G/A for Praxis Precision Medicines, Inc. on February 14, 2024.
    Get the next $EPIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EPIX

    DatePrice TargetRatingAnalyst
    11/4/2024Buy → Hold
    Jefferies
    11/4/2024Outperform → Perform
    Oppenheimer
    11/4/2024$15.00 → $2.00Overweight → Neutral
    Piper Sandler
    6/26/2023$17.00Outperform
    Oppenheimer
    8/17/2021$36.00 → $22.00Outperform
    Oppenheimer
    More analyst ratings

    $EPIX
    SEC Filings

    See more
    • ESSA Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ESSA Pharma Inc. (0001633932) (Filer)

      5/8/25 7:04:05 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ESSA Pharma Inc.

      10-Q - ESSA Pharma Inc. (0001633932) (Filer)

      5/8/25 7:00:30 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13D filed by ESSA Pharma Inc.

      SCHEDULE 13D - ESSA Pharma Inc. (0001633932) (Subject)

      4/24/25 8:56:37 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025

      Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025. "We continue to rigorously evaluate strategic options with a focus on maximizing shareholder value," said David Parkinson, MD, President and CEO of ESSA. "We have taken productive steps tow

      5/8/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

      SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot

      3/6/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024

      Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 11, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal first quarter ended December 31, 2024. "Following our decision to terminate the clinical development of masofaniten, we have been evaluating and reviewing strategic options with a focus on maximizing shareholder valu

      2/11/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ESSA Pharma downgraded by Jefferies

      Jefferies downgraded ESSA Pharma from Buy to Hold

      11/4/24 8:34:37 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma downgraded by Oppenheimer

      Oppenheimer downgraded ESSA Pharma from Outperform to Perform

      11/4/24 7:26:24 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded ESSA Pharma from Overweight to Neutral and set a new price target of $2.00 from $15.00 previously

      11/4/24 7:26:03 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    Leadership Updates

    Live Leadership Updates

    See more

    $EPIX
    Financials

    Live finance-specific insights

    See more

    $EPIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

      SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot

      3/6/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

      SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024  /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berg

      3/7/24 8:13:00 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

      SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024  /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin

      3/7/24 8:13:00 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025

      Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025. "We continue to rigorously evaluate strategic options with a focus on maximizing shareholder value," said David Parkinson, MD, President and CEO of ESSA. "We have taken productive steps tow

      5/8/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024

      Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 11, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal first quarter ended December 31, 2024. "Following our decision to terminate the clinical development of masofaniten, we have been evaluating and reviewing strategic options with a focus on maximizing shareholder valu

      2/11/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024

      Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Dec. 17, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2024. "We recently made the difficult decision to terminate the clinical development of m

      12/17/24 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Parkinson David Ross bought $21,213 worth of shares (9,223 units at $2.30), increasing direct ownership by 16% to 65,675 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      12/18/23 9:57:03 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berger Franklin M bought $133,274 worth of shares (23,259 units at $5.73), increasing direct ownership by 3% to 784,404 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      11/22/23 6:22:47 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berger Franklin M bought $419,661 worth of shares (76,471 units at $5.49), increasing direct ownership by 11% to 760,875 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      11/16/23 5:45:43 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Biotech Growth N V sold $12,018,409 worth of shares (7,879,583 units at $1.53), closing all direct ownership in the company (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      11/5/24 12:06:18 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Virsik Peter sold $4,185 worth of shares (694 units at $6.03), decreasing direct ownership by 8% to 7,776 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      10/7/24 3:00:52 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Virsik Peter sold $4,164 worth of shares (694 units at $6.00), decreasing direct ownership by 8% to 8,470 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      9/9/24 2:03:33 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      11/14/24 7:32:27 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      11/14/24 4:04:37 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      11/14/24 6:56:05 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care